Akums Drugs and Pharmaceuticals Limited, a prominent player in the healthcare sector, has been making significant strides in the pharmaceutical industry both in India and on the international stage. Incorporated in 2004 and headquartered in Delhi, India, the company has established itself as a comprehensive provider of pharmaceutical products and active pharmaceutical ingredients (APIs). With a diverse portfolio that includes drugs, ayurvedic formulations, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, and over-the-counter (OTC) products, Akums Drugs and Pharmaceuticals Limited caters to a wide array of therapeutic areas.
The company’s product offerings span various dosage forms such as tablets, hard and soft gelatin capsules, liquid orals, sachets, vials, ampoules, form-fill-seal products, topical preparations, eye drops, dry powder injections, and gummies. These products address critical therapeutic areas including anti-infectives, pain management, gastroenterology, orthopaedics, cardio-diabetic care, critical care, respiratory, and gynaecology. This extensive range underscores the company’s commitment to addressing diverse healthcare needs and enhancing patient care.
In addition to its manufacturing capabilities, Akums Drugs and Pharmaceuticals Limited operates as a pharmaceutical contract development and manufacturing organization (CDMO). This dual role allows the company to leverage its expertise in both product development and large-scale manufacturing, providing a comprehensive solution to its clients. The CDMO services offered by Akums Drugs and Pharmaceuticals Limited are particularly valuable in an industry where the demand for efficient and reliable manufacturing partners is ever-increasing.
Financially, the company has demonstrated robust performance. As of October 12, 2026, the close price of its stock on the National Stock Exchange of India was INR 769.3. The company’s market capitalization stands at a substantial INR 115,048,546,304, reflecting investor confidence in its growth prospects. Over the past year, the stock has experienced significant volatility, with a 52-week high of INR 838.8 on September 22, 2026, and a 52-week low of INR 409.3 on January 20, 2026. Despite these fluctuations, the company’s price-to-earnings ratio of 43.18 indicates a strong market valuation, suggesting that investors are optimistic about its future earnings potential.
Akums Drugs and Pharmaceuticals Limited’s strategic focus on both domestic and international markets positions it well for sustained growth. The company’s ability to innovate and adapt to changing market dynamics, coupled with its extensive product portfolio and manufacturing capabilities, positions it as a key player in the global pharmaceutical landscape. As the healthcare industry continues to evolve, Akums Drugs and Pharmaceuticals Limited is well-equipped to meet the challenges and opportunities that lie ahead, ensuring its continued success and contribution to global health.
